

A Chau 銀行 (ACB) 2022 年 7 月 29 日


# 買進

### 目標價格上漲/(下跌)+30%

收盤 28/07/2022價格 24.450 越南盾12 個月目標價格 31.883 越南盾

\*派息後調整目標價格

### 股票價格與 VN-Index 之間的相關性



市值	3,5 tỷ USD
6個月平均交易額	6,8 triệu USD
流通股數	3.377 triệu CP
自由轉讓比例	85%
外資持股	30,0%
大股東	30,4%
TS/VCSH 2022E (*)	10,2x
P/E 2022E (*)	6,4x
P/B 2022E (*)	1,4x
剩餘外資額	0,0%
2022 年股息收益率 (*)	0,0%

## 源: Fiinpro, 元大越南

ACB 的業務業績	2022 年第 二季度	% QoQ	% YoY
淨利潤收入(億越南盾)	5.606	+3%	+12%
淨費用收入(億越南盾)	993	+34	+12%
總營業收入調整 (億越 南盾)	6.567	+1%	+5%
合約費用 (億越南盾)	2.276	-1′	+43%
預防(億越南盾)	-267	N/A	-119%
PATMI (億越南盾)	3.943	+20	+52%
NPL (%)	0,76%	+20%	+52%
LLR (%)	181%	-7p	-27ppt
CASA 率(%)	25%	-2ppt	+3ppt
CAR	11,9%		

### 源:企業數據,元大越南

### 分析專家:

Tran Tanh

+84 28 3622 6868 ext 3874

tanh.tran@vuanta.com.vn

Bloomberg code: YUTA

# A Chau 銀行 (ACB)

# 撥回撥備推動利潤

# 事件

ACB 宣布 2022 年第二季度母公司股東 (PATMI) 的稅後利潤為 3 兆 9,000 億越 南盾 (環比增長 20% / 同比增長 52%) , 主要是由於淨利潤收入和淨費用收入 增加,以及撥回撥備。2022 年上半年(1H22), PATMI 達到 7 兆 2,000 億越南盾(同比增長 43%),完成我們全年預測的 63%。

# 焦點

**ACB 的貸款在 1H22 年初至今增長 9.3%。**其中,64% 為個人客戶貸款,29% 為中小企業貸款。然而,年初至今,資本籌集僅增長 +2.2%。貸款/存款比例 (LDR) 為83%,接近國家銀行的85% 限制。

**2022 年第二季度淨利潤收入**為 5 兆 6,000 億越南盾(環比增長 3% / 同比增長 12%)。1H22 淨利潤為 11 兆越南盾(同比增長 15%)。ACB 宣布 2022 年第二季度的淨利潤率 (NIM) 為 4.0%(環比持平/同比 -10 個基點)。

**2022 年第二季度淨費用收入**為 9,930 億越南盾(環比增長 34% / 同比增長 12% )。1H22 淨費用收入同比增長 +15%, 達到 1 兆 7,000 億越南盾。銀行手續費收入佔總手續費收入的 54%, 其次是卡服務(17%)、賬戶服務(12%)、國際支付(11%)和其他服務(6%)。

**2022 年第二季度的營業費用達到 2 兆 3,000 億越南盾 (環比下降 17%/ 同比增長 43%)。** 我們估計成本/收入比率 (CIR) 調整為 35% (環比下降 8ppt/ 同比增長 9ppt)。

ACB 在 2022 年第二季度錄得 2,670 億越南盾的撥備。這是幫助增加 2022 年第二季度收益的主要驅動力。

**截至 2022 年第二季度末,重組後的債務餘額為 13 兆越南盾** (相當於總貸款剩餘的 3%)。

2022 年第二季度的**其他淨收入**(主要是壞賬結算)達到 3,560 億越南盾(環比下降 4%/ 2021 年第二季度虧損 210 億越南盾)。**1H22 壞賬結算**達到 7,250 億越南盾(同比增長 26 倍)。

**該銀行宣布 2022 年第二季度的壞賬覆蓋率 (LLR) 為 181%** (環比下降 7ppt/ 同比下降 27ppt)。2022 年第二季度公佈的**壞賬率 (NPL)** 為 0.76% (環比下降 6bps/ 同比增長 8bps)。

用於中長期貸款的短期資本為20.4%,比國家銀行的上限為37%。

2022 年第二季度末 **CASA 率為 25%**(環比下降 2ppt / 同比增長 3ppt )。2022 年第二季度的資本充足率 (CAR) 為 11.9%,高於巴塞爾協議 II 為 8% 的最低限度

### 觀點

高 LLR 比率幫助 ACB 減少撥備靈活,並幫助推動 2022 年第二季度的利潤。 2022 年第二季度,壞賬結算的復甦情況顯著改善,這顯示 ACB 的資產質量穩健。 ACB 在我們的 2022 年第一季度 CAMEL 排名中名列前茅。資產質量保持穩定,NPL 較低(0.76%),LLR 較高(181%)。 ACB 的 2022 年市盈率是 1.4 倍,比行業中位為 1.3 倍。 ACB 的經營業績和資產質量優於行業平均水平,我們維持對 ACB 的買進建議。

### ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ARE LOCATED IN APPENDIX A.

Yuanta does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors shouldconsider this report as only a single factor in making their investment decision.

# Appendix A: Important Disclosures

### Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

### **Ratings Definitions**

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

#### Global Disclaimer

© 2022 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or andany form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.

Taiwan persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research Yuanta Securities Investment Consulting 4F, 225,
Section 3 Nanking East Road, Taipei 104

Taiwan

Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact:Attn: Research Yuanta Securities (Hong Kong) Co. Ltd 23/F, Tower 1, Admiralty Centre18

Harcourt Road,

Hong Kong

Korean persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Head Office Yuanta Securities Building Euljiro 76 Jung-gu
Seoul, Korea 100-845

Tel: +822 3770 3454

Indonesia persons wishing to obtain further information on any of the securities mentioned in this publication should contact:Attn: Research PT YUANTA SECURITIES INDONESIA

(A member of the Yuanta Group) Equity

Tower, 10th Floor Unit EFGHSCBD Lot

9

Jl. Jend. Sudirman Kav. 52-53 Tel:

(6221) - 5153608 (General)

Thailand persons wishing to obtain further information on any of the securities mentioned in this publication should contact:Research department

Yuanta Securities (Thailand) 127 Gaysorn Tower, 16th floor

Ratchadamri Road, Pathumwan

Bangkok 10330

Vietnam persons wishing to obtain further information on any of the securities mentioned in this publication should contact:Research department Yuanta Securities (Vietnam)

4th Floor, Saigon Centre Tower 1,

65 Le Loi Boulevard, Ben Nghe

Ward, District 1, HCMC, Vietnam

# YUANTA SECURITIES NETWORK



### YUANTA SECURITIES VIETNAM OFFICE

Head office: 4th Floor, Saigon Centre, Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

# Matthew Smith, CFA

Head of Research

Tel: +84 28 3622 6868 (ext. 3815) matthew.smith@yuanta.com.vn

# Tanh Tran Analyst

(Banks)

Tel: +84 28 3622 6868 (ext. 3874) tanh.tran@yuanta.com.vn

# Di Luu

Assistant Analyst

Tel: +84 28 3622 6868 (ext. 3845) di.luu@yuanta.com.vn

### Institutional Sales

# Anh Nguyen

Sales Trader Supervisor Tel: +84 28 3622 6868 (ext. 3909) anh.nguyen2@yuanta.com.vn

# Dat Bui Sales

Trader

Tel: +84 28 3622 6868 (ext. 3941) dat.bui@yuanta.com.vn

# Binh Truong

Deputy Head of Research (O&G, Energy)Tel: +84 28 3622 6868 (ext. 3845) binh.truong@yuanta.com.vn

# Tam Nguyen Analyst

(Property)

Tel: +84 28 3622 6868 (ext. 3874) tam.nguyen@yuanta.com.vn

# Trung NguyenSales

Trader

Tel: +84 28 3622 6868 (ext. 3890) trung.nguyen1@yuanta.com.vn

## Vi Truong

Sales Trader

Tel: +84 28 3622 6868 (ext. 3940) vi.truong@yuanta.com.vn